Qingming Yang

No. 28 Fuxing Road, 
Beijing, CN 
No. 28 Fuxing Road, 
Beijing, CN 
OverviewLocationsClinical Research

Overview

Qingming Yang practices in Beijing, China. Their top areas of expertise are Hodgkin Lymphoma, Mouth Ulcers, B-Cell Lymphoma, and Acute Lymphoblastic Leukemia (ALL).

Their clinical research consists of co-authoring 25 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years.

Locations

No. 28 Fuxing Road, Beijing, 100853, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Randomized, Single-blind, Placebo-controlled, Phase 2 Study to Evaluate the Safety and Efficacy of the Pan-immunotherapy in Subjects With Relapsed/Refractory Ovarian Cancer
A Randomized, Single-blind, Placebo-controlled, Phase 2 Study to Evaluate the Safety and Efficacy of the Pan-immunotherapy in Subjects With Relapsed/Refractory Ovarian Cancer
Enrollment Status: Completed
Publish Date: July 15, 2024
Intervention Type: Drug
Study Drugs: Manganese Chloride, Nab-paclitaxel, Platinum chemotherapy, Sintilimab
Study Phase: Phase 2
Anti-PD-1 Antibody SHR-1210 Alone or in Combination With Decitabine in Relapsed or Refractory Hodgkin Lymphoma:an Open-label Phase II Trial
Anti-PD-1 Antibody SHR-1210 Alone or in Combination With Decitabine in Relapsed or Refractory Hodgkin Lymphoma:an Open-label Phase II Trial
Enrollment Status: Unknown
Publish Date: April 01, 2019
Intervention Type: Drug
Study Drugs: SHR-1210 Anti-PD-1 Antibody, Decitabine
Study Phase: Phase 2
View 1 Less Clinical Trial

25 Total Publications

Inhibition of glycosphingolipid synthesis with eliglustat in combination with immune checkpoint inhibitors in advanced cancers: preclinical evidence and phase I clinical trial.
Inhibition of glycosphingolipid synthesis with eliglustat in combination with immune checkpoint inhibitors in advanced cancers: preclinical evidence and phase I clinical trial.
Journal: Nature communications
Published: May 14, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Yang's expertise for a condition
ConditionClose
        View All 10 Experienced Conditions
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile